We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
VRAX | Virax Biolabs Group Ltd | 1.955 | 0.885 | 82.71% | 69,580,945 |
TOIIW | Oncology Institute Inc | 0.0286 | 0.0119 | 71.26% | 3,882 |
WISA | WiSA Technologies Inc | 3.395 | 1.33 | 64.01% | 38,261,619 |
FRGT | Freight Technologies Inc | 1.01 | 0.38496 | 61.59% | 191,968,011 |
SHOTW | Safety Shot Inc | 0.389 | 0.129 | 49.62% | 497 |
FBLG | FibroBiologics Inc | 9.90 | 3.20 | 47.76% | 2,386,109 |
AEMD | Aethlon Medical Inc | 0.611 | 0.1724 | 39.31% | 84,205,968 |
AONC | American Oncology Network Inc | 3.03 | 0.77 | 34.07% | 1,482,322 |
CLEU | China Liberal Education Holdings Ltd | 1.87 | 0.45 | 31.69% | 9,051,752 |
REPL | Replimune Group Inc | 7.17 | 1.61 | 28.96% | 3,122,938 |
BNAI | Brand Engagement Network Inc | 4.51 | 1.01 | 28.86% | 1,122,380 |
WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, is pleased to report seeing continued penetration into the $296 billion wireless audio market fueled by interest in its WiSA E software.
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
No Shareholder Action Required at This TimeWASHINGTON, June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,960.90 | -116.39 | -0.16% | 1.39T | 3,198,972,379 |
ETH | Ethereum | 3,829.55 | -34.66 | -0.90% | 462.15B | 1,918,607,249 |
BNB | Binance Coin | 702.33 | 3.67 | 0.53% | 110.47B | 516,242,217 |
USDT | Tether USD | 0.99959 | -0.00041 | -0.04% | 97.8B | 225,747,420 |
SOL | Solana | 171.60 | -1.84 | -1.06% | 76.1B | 518,987,776 |
STETH | stETH | 3,802.78 | -59.89 | -1.55% | 37.71B | 4,753,346 |
XRP | Ripple | 0.5252 | -0.0004 | -0.08% | 28.69B | 234,230,763 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 860,372,008 |
TONCOIN | Wrapped TON Coin | 7.33 | 0.158634 | 2.21% | 25.72B | 108,895,296 |
DOGE | Dogecoin | 0.16188 | -0.0012 | -0.74% | 23.3B | 198,614,661 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions